1. Home
  2. NAAS vs AYTU Comparison

NAAS vs AYTU Comparison

Compare NAAS & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NaaS Technology Inc.

NAAS

NaaS Technology Inc.

N/A

Current Price

$2.57

Market Cap

21.5M

ML Signal

N/A

Logo Aytu BioPharma Inc.

AYTU

Aytu BioPharma Inc.

HOLD

Current Price

$2.60

Market Cap

25.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NAAS
AYTU
Founded
2019
N/A
Country
China
United States
Employees
N/A
N/A
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.5M
25.7M
IPO Year
2017
2015

Fundamental Metrics

Financial Performance
Metric
NAAS
AYTU
Price
$2.57
$2.60
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$9.33
AVG Volume (30 Days)
3.5K
45.8K
Earning Date
03-31-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$27,632,080.00
Revenue This Year
$378.49
N/A
Revenue Next Year
N/A
$43.75
P/E Ratio
N/A
N/A
Revenue Growth
N/A
277.47
52 Week Low
$0.41
$0.95
52 Week High
$4.54
$3.07

Technical Indicators

Market Signals
Indicator
NAAS
AYTU
Relative Strength Index (RSI) 49.24 54.63
Support Level $2.22 $2.14
Resistance Level $3.43 $2.66
Average True Range (ATR) 0.16 0.10
MACD 0.05 0.00
Stochastic Oscillator 51.43 60.87

Price Performance

Historical Comparison
NAAS
AYTU

About NAAS NaaS Technology Inc.

Naas Technology Inc is an electric vehicle charging service provider in China, whose vision is to power the world with carbon-neutral energy. It offers an integrated set of online solutions to charging station operators, a wide range of offline services that simplify the daily operations of charging station operators, and non-charging services such as food and beverage services to station operators.

About AYTU Aytu BioPharma Inc.

Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.

Share on Social Networks: